Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Solidago Virgaurea, Uva-ursi, Pareira Brava, Sabal Serrulata, Populus Tremuloides, Staphysagria, Cantharis, Terebinthia, Borax
Brand Name
Solidago
Generic Name
Solidago Virgaurea, Uva-ursi, Pareira Brava, Sabal Serrulata, Populus Tremuloides, Staphysagria, Cantharis, Terebinthia, Borax
Active Ingredient
Arctostaphylos Uva-ursi LeafCategory
Non-Standardized Food Allergenic Extract [EPC]
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 1 [hp_X]/mL | LIQUID | ORAL | 60986-1020 |
Detailed information about Solidago
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Solidago, you must consult a qualified healthcare professional.
Arctostaphylos Uva-ursi Leaf is a botanical extract classified as a non-standardized allergenic extract and nitrogen-binding agent, primarily utilized for its urinary antiseptic properties and in specialized diagnostic allergy testing.
Dosage for Arctostaphylos Uva-ursi Leaf varies significantly based on the concentration of the active constituent, arbutin. For therapeutic urinary antisepsis, the goal is to achieve a sufficient concentration of hydroquinone in the bladder.
Arctostaphylos Uva-ursi Leaf is NOT recommended for pediatric use. Due to the presence of hydroquinone, which can be toxic in high concentrations, and the high tannin content which can cause severe gastric distress in children, safety and efficacy have not been established for patients under the age of 18. Healthcare providers should seek alternative treatments for urinary conditions in children.
Use with extreme caution. Since the active metabolites are cleared by the kidneys, patients with a Glomerular Filtration Rate (GFR) below 30 mL/min may experience accumulation of hydroquinone, increasing the risk of systemic toxicity. Dose reduction or avoidance is typically advised.
Because the liver is responsible for the conjugation of hydroquinone, patients with significant hepatic cirrhosis or failure may have impaired metabolism. This can lead to higher levels of free hydroquinone in the blood. Monitoring for signs of toxicity is required.
Elderly patients often have age-related declines in renal function. Start at the lower end of the dosing range and monitor renal function (BUN/Creatinine) closely. The risk of gastric irritation from tannins is also higher in this population.
To maximize the efficacy of Arctostaphylos Uva-ursi Leaf, specific administration protocols must be followed:
If a dose is missed, take it as soon as remembered. However, if it is nearly time for the next scheduled dose, skip the missed dose and resume the regular schedule. Do not double the dose to make up for a missed one, as this increases the risk of hydroquinone toxicity.
Overdose of Arctostaphylos Uva-ursi Leaf can be serious due to the hydroquinone content. Signs of acute overdose include:
In the event of a suspected overdose, contact a Poison Control Center or emergency services immediately. Emergency measures include gastric lavage and supportive care to manage respiratory and neurological symptoms.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Limit use to no more than 5 consecutive days unless otherwise directed by a physician.
The most frequent side effects associated with Arctostaphylos Uva-ursi Leaf are related to its high tannin concentration and the presence of hydroquinone metabolites.
> Warning: Stop taking Arctostaphylos Uva-ursi Leaf and call your doctor immediately if you experience any of these.
Arctostaphylos Uva-ursi Leaf is strictly intended for short-term use (no more than 5-7 days at a time). Long-term use (months or years) is associated with significant risks:
No FDA black box warnings currently exist for Arctostaphylos Uva-ursi Leaf as a botanical extract. However, healthcare providers are warned against its use in patients with pre-existing renal or hepatic disease due to the narrow therapeutic index of its primary metabolite, hydroquinone.
Report any unusual symptoms to your healthcare provider. For more information on side effects, you may contact the FDA at 1-800-FDA-1088.
Arctostaphylos Uva-ursi Leaf is a potent pharmacological agent and should not be viewed as a 'harmless' herbal supplement. Its active metabolite, hydroquinone, is a phenolic compound that requires careful monitoring. Patients must be aware that this medication is only effective for urinary tract infections when the urine is alkaline. If the urine is acidic, the treatment will likely fail, and the infection may progress to the kidneys (pyelonephritis).
No FDA black box warnings for Arctostaphylos Uva-ursi Leaf. However, clinicians should treat the potential for hydroquinone toxicity with the same gravity as a boxed warning, particularly regarding duration of use and pediatric contraindications.
For patients prescribed clinical-grade Uva-ursi or those using it under medical supervision for more than a few days, the following may be monitored:
Arctostaphylos Uva-ursi Leaf generally does not cause sedation. However, if a patient experiences rare side effects like dizziness, tinnitus, or irritability, they should refrain from driving or operating heavy machinery until these symptoms resolve.
Alcohol should be avoided while taking Arctostaphylos Uva-ursi Leaf. Alcohol can irritate the bladder, potentially worsening UTI symptoms, and may place additional metabolic stress on the liver, which is already processing hydroquinone conjugates.
There is no known withdrawal syndrome associated with the discontinuation of Uva-ursi. However, if the medication is stopped before the infection is fully cleared, symptoms may return. If an allergic reaction occurs, the medication must be discontinued immediately and permanently.
> Important: Discuss all your medical conditions with your healthcare provider before starting Arctostaphylos Uva-ursi Leaf.
To manage these interactions, healthcare providers should perform a comprehensive review of the patient's medication list. The primary strategy is to ensure the patient avoids all acidifying agents and maintains an alkaline urinary pH. If iron or other minerals are required, they must be administered at a different time of day than the Uva-ursi dose.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Arctostaphylos Uva-ursi Leaf must NEVER be used in the following circumstances:
Conditions requiring careful risk-benefit analysis include:
Patients with known hypersensitivities to other members of the Ericaceae family (e.g., blueberries, cranberries, huckleberries, or azaleas) may experience cross-allergic reactions when using Arctostaphylos Uva-ursi Leaf. If a patient has had a previous reaction to hydroquinone-containing skin lightening creams, they should avoid oral Uva-ursi.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Arctostaphylos Uva-ursi Leaf.
Arctostaphylos Uva-ursi Leaf is strictly contraindicated during pregnancy. There are two primary concerns:
It is not known exactly how much hydroquinone is excreted into human milk, but given its low molecular weight and chemical properties, passage is highly likely. Because hydroquinone is a cellular toxin, the risk to a developing infant's liver and kidneys is significant. Breastfeeding should be discontinued if Uva-ursi is required, or more likely, an alternative antibiotic should be used that is compatible with nursing.
Arctostaphylos Uva-ursi Leaf is not approved for use in children. The metabolic pathways required to detoxify hydroquinone may not be fully mature in younger children, and the risk of methemoglobinemia is higher in this population. Pediatric urinary tract infections should always be managed with standard-of-care antibiotics under the supervision of a pediatrician.
In patients over 65, the use of Uva-ursi requires caution due to:
Arctostaphylos Uva-ursi Leaf is generally avoided in patients with a GFR < 60 mL/min. In patients with severe impairment (GFR < 30 mL/min), it is absolutely contraindicated. The kidneys are both the site of action and the primary route of elimination; impaired kidneys may be further irritated by the hydroquinone while failing to clear it, creating a dangerous feedback loop of toxicity.
Patients with Child-Pugh Class B or C hepatic impairment should not use Uva-ursi. The liver’s ability to conjugate hydroquinone with glucuronide is essential for its safe transit through the blood. Failure to conjugate leads to higher levels of 'free' hydroquinone in the systemic circulation, which can cause oxidative stress and damage to red blood cells.
> Important: Special populations require individualized medical assessment.
Arctostaphylos Uva-ursi Leaf functions primarily through its prodrug constituent, arbutin. Arbutin is a glycosylated hydroquinone. The molecular mechanism involves several steps:
Additionally, the extract's classification as an Acetylcholine Release Inhibitor [MoA] suggests that certain constituents may interfere with the calcium-dependent release of acetylcholine at nerve terminals, though this is not the primary mechanism for its anti-infective use.
The onset of the antiseptic effect typically occurs within 3 to 4 hours after the first dose, coinciding with peak urinary excretion. The duration of effect is short, lasting approximately 6 hours, which is why dosing 3–4 times daily is required. Tolerance does not typically develop because the drug is used for very short durations.
| Parameter | Value |
|---|---|
| Bioavailability | 70% - 90% (as Arbutin) |
| Protein Binding | < 30% |
| Half-life | 3 - 4 hours (metabolites) |
| Tmax | 1 - 2 hours |
| Metabolism | Hepatic (Glucuronidation/Sulfation) |
| Excretion | Renal (> 75%) |
Arctostaphylos Uva-ursi Leaf is a botanical urinary anti-infective. Within the EPC (Established Pharmacologic Class) system, it is recognized as a Non-Standardized Plant Allergenic Extract and a Nitrogen Binding Agent. It is chemically related to other hydroquinone-containing plants but is unique in its high concentration of arbutin and tannins.
Common questions about Solidago
Arctostaphylos Uva-ursi Leaf is primarily used as a short-term urinary antiseptic to treat mild, uncomplicated urinary tract infections (UTIs) like cystitis. Its active component, arbutin, converts into hydroquinone in the bladder, which helps kill bacteria like E. coli. Additionally, in clinical settings, it is used as an allergenic extract for diagnostic skin testing to identify plant allergies. It may also be used in specialized cases for its nitrogen-binding properties to manage metabolic waste. It is not intended for long-term use or for treating serious kidney infections.
The most common side effects include nausea, vomiting, and stomach discomfort, which are often caused by the high tannin content in the leaves. A very common but harmless side effect is the discoloration of urine, which may turn greenish-brown or dark brown during treatment. Some patients may also experience mild irritability or difficulty sleeping. If these symptoms become severe or if you experience ringing in the ears, you should stop taking the medication and consult your doctor. Because of the risk of stomach irritation, it is often recommended to take the supplement with food.
It is strongly advised to avoid alcohol while taking Arctostaphylos Uva-ursi Leaf. Alcohol can irritate the bladder and urinary tract, which may worsen the symptoms of the infection you are trying to treat. Furthermore, both alcohol and the metabolites of Uva-ursi are processed by the liver, and combining them can increase the metabolic strain on this organ. Alcohol can also interfere with the hydration levels needed to effectively flush the urinary system. For the best results and safety, stick to water and non-acidic beverages during your treatment course.
No, Arctostaphylos Uva-ursi Leaf is not safe to use during pregnancy and is considered contraindicated. It contains substances that can stimulate the uterus, which may increase the risk of miscarriage or premature labor. Additionally, its active metabolite, hydroquinone, is a potent chemical that could potentially harm the developing fetus. There is also a lack of sufficient clinical data to guarantee safety for the baby. Pregnant women should always consult their healthcare provider for safer, standard antibiotic treatments for urinary tract infections.
Arctostaphylos Uva-ursi Leaf typically begins to work within 3 to 4 hours after the first dose, as this is when the active hydroquinone reaches peak levels in the urine. However, it may take 24 to 48 hours of consistent dosing to notice a significant reduction in UTI symptoms like burning or urgency. It is vital to ensure your urine is alkaline (not acidic) for the drug to be activated. If symptoms do not improve after 48 hours, or if they get worse, you should contact a healthcare provider immediately. Treatment should not exceed 7 consecutive days.
Yes, you can stop taking Arctostaphylos Uva-ursi Leaf suddenly, as it does not cause physical dependence or withdrawal symptoms. However, if you are using it to treat an active urinary infection, stopping too early may allow the bacteria to multiply again, leading to a relapse of the infection. It is generally recommended to finish the short course (usually 5 days) as directed by your healthcare provider. If you are stopping because of a side effect like nausea or an allergic reaction, you should notify your doctor to find an alternative treatment. Never use the product for more than 7 days at a time.
If you miss a dose of Arctostaphylos Uva-ursi Leaf, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular timing. Do not take two doses at once to make up for the one you missed, as this can increase the concentration of hydroquinone in your system and lead to toxicity. Maintaining a consistent level of the herb in your urine is important for its antiseptic effect. Setting a reminder on your phone can help you stay on track with the 3 to 4 daily doses typically required.
There is no clinical evidence to suggest that Arctostaphylos Uva-ursi Leaf causes weight gain. The medication is used for short-term periods (less than a week), which is generally not long enough to affect body weight or metabolism significantly. If you notice sudden weight gain or swelling (edema) in your legs or ankles while taking this medication, it could be a sign of a serious kidney problem rather than typical weight gain. In such cases, you should seek medical attention immediately. Always report unexpected physical changes to your healthcare provider.
Arctostaphylos Uva-ursi Leaf has several important drug interactions. It should not be taken with any medication or supplement that makes the urine more acidic, such as Vitamin C, cranberry juice, or ammonium chloride, as these prevent the herb from working. It may also interact with NSAIDs like ibuprofen, increasing the risk of stomach irritation. Because it contains tannins, it can prevent the absorption of iron supplements if taken at the same time. Always provide your doctor or pharmacist with a full list of your current medications and supplements before starting Uva-ursi.
Arctostaphylos Uva-ursi Leaf is a botanical substance, so the term 'generic' applies differently than it does to synthetic drugs. It is widely available under its botanical name or as 'Bearberry' from many different manufacturers as a dietary supplement. However, for clinical diagnostic purposes, specific non-standardized allergenic extracts are produced by specialized pharmaceutical companies. When buying over-the-counter versions, look for products standardized to arbutin content (usually 20%) to ensure you are getting a consistent dose. Always choose a reputable brand that follows Good Manufacturing Practices (GMP).
Other drugs with the same active ingredient (Arctostaphylos Uva-ursi Leaf)